Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human thrombopoietin + thalidomide
- Development stage
- Preclinical
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
This is a combination therapy consisting of recombinant human thrombopoietin (rhTPO) and thalidomide. Recombinant human thrombopoietin is a biologic agent that mimics endogenous thrombopoietin, the primary regulator of platelet production, by stimulating megakaryocyte proliferation and differentiation to increase platelet counts. Thalidomide is an immunomodulatory small molecule with anti-angiogenic and anti-inflammatory properties; it inhibits tumor necrosis factor-alpha (TNF-α) production, modulates cytokine release, and affects T-cell function. This combination has been explored for hematologic disorders where both stimulation of platelet production (via rhTPO) and immunomodulation/anti-angiogenesis (via thalidomide) may be beneficial.
- Other names
- recombinant human thrombopoietin and thalidomide
02
Targets
CRBN (Cereblon)TPOR (Thrombopoietin receptor)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on recombinant human thrombopoietin + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human thrombopoietin + thalidomide.